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Global migration has resulted in a large number of 
asylum applications in Europe. In 2014, clusters 
of  Plasmodium vivax  cases were reported among 
newly arrived Eritreans. This study aimed to assess 
malaria among Eritrean migrants in Europe from 2011 
to 2016. We reviewed European migration numbers 
and malaria surveillance data for seven countries 
(Denmark, Germany, Netherlands, Norway, Sweden, 
Switzerland and the United Kingdom) which received 
44,050 (94.3%) of 46,730 Eritreans seeking asylum in 
Europe in 2014. The overall number of malaria cases, 
predominantly P. vivax, increased significantly in 2014 
compared to previous years, with the largest increases 
in Germany (44 P. vivax cases in 2013 vs 294 in 2014, 
p  <  0.001) and Sweden (18 in 2013 vs 205 in 2014, 
p  <  0.001). Overall, malaria incidence in Eritreans 
increased from 1–5 to 25 cases per 1,000, and was 
highest in male teenagers (50 cases/1,000). In conclu-
sion, an exceptional increase of malaria cases occurred 
in Europe in 2014 and 2015, due to rising numbers of 
Eritreans with high incidence of  P. vivax  arriving in 
Europe. Our results demonstrate potential for rapid 
changes in imported malaria patterns, highlighting 
the need for improved awareness, surveillance efforts 
and timely healthcare in migrants.
Introduction
Between 2010 and 2013, approximately 5,200 to 5,700 
cases of imported malaria were reported annually in 
Europe, in both travellers and migrants [1]. Most cases 
were caused by  Plasmodium falciparum  acquired in 
sub-Saharan Africa. Plasmodium vivax was the second 
most common species, accounting for approximately 
10% to 25% of cases and was mainly acquired in Asia 
[2,3]. Europe saw a large increase in asylum seekers 
from 2013 to 2015, including people from malaria-
endemic countries. To what extent the patterns of 
imported malaria are affected by changing migration 
patterns has not yet been explored.
Sporadic reports of P. vivax cases among newly arrived 
Eritrean migrants were published in early 2014 [4-6] 
and a review of clinical records and national surveil-
lance data in Sweden revealed a sudden increase in 
overall imported malaria cases, predominantly due 
to P. vivax, among newly arrived Eritreans, a group not 
previously noted for high numbers of imported malaria 
[4]. A similar increase in  P. vivax  cases between 2014 
and 2015 was reported from Germany [5], Norway [6], 
the Netherlands [7], Denmark [8] and Switzerland [9].
The aim of this study was to establish the extent of 
malaria in Eritrean migrants in Europe in the period from 
2011 to 2016. We performed an analysis of European 
migration data and analysed malaria surveillance data 
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from the seven countries receiving the majority of 
Eritrean asylum applications in Europe during 2014 and 
2015. In addition, we performed a retrospective review 
of clinical data from Germany and Sweden.
Methods
Migration data
Data on asylum applications from Eritrean citizens 
in 32 European countries between 2011 and 2016 
were retrieved from the Eurostat database [10]. This 
included 28 European Union countries as well as the 
European Free Trade Agreement (EFTA) countries 
Iceland, Liechtenstein, Norway and Switzerland. In 
addition, weekly data on Eritrean asylum applications 
in Sweden from 2011 to 2016 were available at the 
Swedish Migration Agency in Sweden.
Malaria surveillance data
Public health agencies in the seven countries 
(Denmark, Germany, The Netherlands, Norway, 
Sweden, Switzerland, and the United Kingdom (UK)) 
reporting > 2000 asylum applications from Eritrean citi-
zens in 2014 were contacted with a request for malaria 
surveillance data from 2011 to 2016. The requested 
data included overall number of malaria cases and 
cases among Eritrean migrants by Plasmodium species 
and available data on patient origin with definitions 
of newly arrived Eritreans described in the various 
countries, (Table 1). The agencies included were 
Statens Serum Institute (SSI) in Denmark, Robert Koch 
Institute (RKI) in Germany, the Centre for Infectious 
Disease Control at the National Institute for Public 
Health and the Environment in the Netherlands (RIVM), 
the Norwegian Institute of Public Health, the Public 
Health Agency of Sweden, the Federal Office of Public 
Health in Switzerland, and Public Health England (PHE) 
in the UK.
A more in-depth review was performed using surveil-
lance and clinical data from Germany and Sweden, the 
two countries with the highest number of Eritrean asy-
lum seekers.
Clinical data
In addition to surveillance data, medical records of 
Eritreans diagnosed with malaria at adult and paediat-
ric hospital units in Sweden (21 hospitals in 17 of 21 
counties) and Hamburg, Germany, from 2014 and 2015 
were reviewed for clinical data and migration history.
Ethical statement
The clinical review was performed with permission 
from the Regional Ethical Review Board, Sweden (EPN 
2009/1328-31/5, 2010/1080-32 and 2012/1155-32). In 
Germany the study was granted exemption according 
to local law by Ärztekammer Hamburg from requiring 
ethics approval because it was a retrospective analysis 
on anonymised patient data.
Statistical analyses
Statistical analyses were performed using Stata version 
13 (StataCorp, College Station, Texas, United States). 
Categorical data was compared using chi-squared 
or Fisher ś exact tests, and continuous data using 
Wilcoxon-Mann-Whitney test. The number of malaria 
cases among Eritrean asylum seekers was calculated 
per 1,000 Eritreans arriving in the corresponding year. 
All model-based comparisons were made using Poisson 
regressions. To compare the rate of malaria infections 
in different years within the group of Eritrean asylum 
seekers, we used the number of malaria cases among 
recently arrived Eritreans (as defined in the national 
surveillance data) as outcome and total number of 
recently arrived Eritreans (asylum applications) as 
exposure. Univariate models were used to relate differ-
ent lags (0–20 weeks) of the weekly number of Eritrean 
asylum applications and P. vivax cases in Sweden from 
2011 to 2016, defining the highest McFadden R-squared 
[11] as the strongest association for weekly number 
of asylum applications predicting the number of  P. 
vivax  cases. Haemoglobin levels were correlated with 
symptom duration by the Spearman correlation.
Results
Migration data
In 2014, 46,730 (7.1%) of the 662,165 asylum applica-
tions in Europe were submitted by Eritreans, a statisti-
cally significant increase compared to previous years 
(Table 1, Supplementary Figure S1 p < 0.001). Eritreans 
constituted the largest group of asylum applicants 
from sub-Saharan Africa in Europe in 2014, followed by 
citizens from Nigeria (n  =  21,330, 3.2%) and Somalia 
(n = 20,155, 3.0%) (p < 0.001).
Seven countries received 44,050 (94.3%) of 46,730 
Eritreans seeking asylum in Europe in 2014 (in 
descending order): Germany, Sweden, Switzerland, 
Netherlands, Norway, Denmark, and the UK (range: 
2,275–13,255) (Table 1). The remaining 25 EU/EFTA 
countries reported a median of 10 applications (range: 
0–820).
The number of Eritreans coming to Europe to seek asy-
lum in 2015 and 2016 remained at similar levels: 47,025 
(3.4%) of 1,392,655, and 40,260 (3.2%) of 1,255,600 
asylum applications in Europe were from Eritrean citi-
zens, respectively, and again mainly in the same seven 
countries (93.7%). A large proportion of Eritreans seek-
ing asylum in Europe in 2014 and 2015 were minors 
aged <  18 years: 8,515 (18.2%) and 12,120 (25.8%), 
respectively (Table 1). A majority were males: in 2014 
the proportion was 34,375 of 46,730 (73.5%) and in 
2015 33,055 of 47,025 (70.3%).
Total number of malaria cases
The total number of malaria cases notified in the seven 
countries increased markedly in 2014 (n=3,771) com-
pared to previous years (2011: 2,871, 2012: 2,463 and 


























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































vivax was the main species accounting for the increase 
and the proportion of malaria cases diagnosed as  P. 
vivax increased in 2014 (Table 1).
Malaria cases in Eritreans
We estimated the incidence of malaria in Eritreans per 
1,000 Eritrean asylum applications in the seven respec-
tive countries. The incidence rate increased notably in 
2014 (18/1,000) and remained at a similar level dur-
ing 2015 (15/1,000) (Table 1). During 2016, the overall 
incidence returned to a lower level (6/1,000), similar 
to that seen from 2011 to 2013. The increase was only 
seen for P. vivax in 2014 and 2015, whereas the P. falci-
parum  incidence in Eritreans remained low (<  1/1,000) 
between 2011 and 2016 in all countries.
The overall mean incidence from the seven countries 
was then used to estimate the total number of malaria 
cases in Eritrean asylum applicants in Europe: 47 
among 20,300 Eritrean applicants in 2013, 823 among 
46,730 in 2014, 686 among 47,025 in 2015, and 253 
among 40,260 Eritreans in 2016 (Table 1).
Germany
Germany was the European country which received the 
highest number of asylum applications from Eritrea, 
with 13,255 in 2014, 10,990 in 2015 and 19,100 in 
2016. The overall number of notified malaria cases, 
predominantly  P. vivax, increased significantly in 
2014 compared to previous years (44  P. vivax  cases 
in 2013 versus 294 in 2014, p  <  0.001). The incidence 
of malaria among Eritreans increased notably in 2014 
with 19.0 cases per 1,000 (95% confidence interval 
(CI): 16.7–21.5) and remained high in 2015 with 17.9 
(95% CI: 15.5–20.6). Cases were predominantly in male 
patients with 227 of 252 (90.1%) in 2014 and 176 of 
197 (89.3%) in 2015. The median age was 20 years in 
2014 and 2015. During 2016 the incidence was similar 
to the period prior to 2014 (Table 1). Malaria incidence 
in children (≤  13 years) was 0 per 1,000 in 2013 and 
2015, while teenagers aged 14 to 17 years had a high 
incidence in 2014 and 2015 (Figure 1). Year of arrival 
in Germany was available in the health surveillance 
data and 92% (95% CI: 89–95%) of malaria cases in 
Eritrean citizens in 2014 and 2015 were diagnosed in 
the year of arrival (Supplementary Table S2).
The clinical presentation of malaria in Eritreans was 
assessed by reviewing clinical records of 66 patients 
at the University Medical Centre Hamburg-Eppendorf 
during 2014 and 2015. In total, 52 of 66 patients with 
ICD10 code B51 (P. vivax malaria), and none of the 130 
patients with ICD10 code B50 (P. falciparum  malaria) 
were Eritreans. Median age was 19 years (range: 12–52 
years) and 44 patients (84.6%) were male. Patients 
reported a migration route starting in Eritrea and 
travelling through Ethiopia and/or Sudan, and then to 
Libya before crossing the Mediterranean Sea to Europe 
(Table 2). Some 38 (73.1%) patients reported that they 
had already been treated for malaria on the way to their 
destination country and one patient presented with 
severe malaria anaemia. The median symptom dura-
tion prior to contact with healthcare professionals in 
Hamburg was 3 days (range: 1–180) (Table 2). The pro-
portion of P. vivax relapses after treatment in Germany 
was 7.8% (4/52).
Sweden
Sweden received 11,530 Eritrean asylum applications 
in 2014, 7,230 in 2015 and 1,150 in 2016 (Table 1). In 
Sweden, 119 malaria cases were reported in 2013 
and 354 cases in 2014 (197% increase, p  <  0.001). 
The increase was predominant for  P. vivax  (18 cases 
in 2013 versus 205 in 2014, p  <  0.001). The incidence 
among Eritreans across age groups was estimated in 
Sweden from 2013 to 2015, with the highest estimated 
incidence in the 14–17-year age group with up to 50.7 
cases per 1,000 Eritrean males (corresponding to 
1 case/20 teenagers) in Sweden in 2014 (Figure 1). 
In 2015, the incidence in 14–17-year-olds declined, 
whereas it remained stable in adults.
The weekly number of  P. vivax  cases in Sweden 
followed the number of Eritrean asylum applications, 
with a time lag of 5 weeks (McFadden’s R-squared: 
0.31); and although the number of applications from 
Eritreans started to increase in 2013,  P. vivax  malaria 
cases did not rise before spring 2014 (Figure 2).
In Sweden, 210 medical records from 21 hospitals were 
reviewed, representing 69.7% of the 307 notified cases 
in newly arrived Eritreans during 2014 and 2015. The 
cases had a mean age of 21 years (range: 2–61) and 
154 (72.9%) were males (Table 2). Twenty patients 
(9.5%) fulfilled the World Health Organization (WHO) 
criteria for severe malaria [12] (19 with  P. vivax  and 
two with  P. vivax  and  P. falciparum  mixed infection); 
and two were admitted to intensive care unit (one 
with vivax malaria and impaired consciousness and 
one with vivax malaria and severe anaemia). The most 
common sign of severe illness was severe anaemia 
(n  =  12) with (haemogloblin level of 37–66 g/L (nor-
mal value: 117–164 g/L); and 20 patients with haemo-
globlin levels between 37 and 93 g/L received blood 
transfusions. Haemogloblin levels were inversely cor-
related with symptom duration (Spearman =  −0.37, 
p < 0.001), and patients with severe malaria tended to 
have longer symptom duration (p = 0.087). Lower age 
was significantly associated with decreased haemo-
globlin levels (Spearman = 0.177, p = 0.0053), but not 
with symptom duration (Spearman = 0.01, p = 0.82), or 
severe malaria (Wilcoxon -Mann-Whitney test p = 0.9). 
The proportion of  P. vivax  relapses after treatment in 
Sweden was 8.1%.
Treatment for malaria along the route of travel to 
Sweden was reported in 105 (50%) of cases in Sweden 
(data were missing for 55 patients) and median symp-
tom duration before healthcare contact in Sweden 
was 3 days (range: 0–180 days) (Table 2). Patients 
reported a migration route starting in Eritrea and trav-
elling through Ethiopia and/or Sudan, and then to 
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Libya before crossing the Mediterranean Sea to Europe 
(Table 2). These countries were reported as country of 
infection in the national malaria statistics in Sweden 
and accounted for the overall increase in 2014 and 
2015 (Figure 3); only 10 of the 205  P. vivax  cases in 
2014 had other countries of infection (India, Pakistan, 
Afghanistan, Tanzania, Somalia, Peru and Papua New 
Guinea). When comparing individual data for 209 
medical records from 2014 and 2015 with those stated 
in the surveillance data, the countries of infection 
matched in 62 (29.5%) patients, differed in 34 of 209, 
and were missing in the medical records of 105 patients 
(50.5%). Eight of 209 patients could not be identified in 
the national database. Hence, in 34 of the 96 patients 
with stated country of infection in both surveillance 
and medical record, the countries did not match.
Switzerland
Switzerland received between 6,920 and 9,965 annual 
Eritrean asylum applicants in 2014 to 2016. The total 
number of malaria cases approximately doubled during 
this time period compared to the period 2011 to 2013, 
and the increase was predominantly due to malaria 
in Eritreans (Table 1). This group represented 3 to 12 
cases annually in 2011 to 2013 and 46 to 151 in the fol-
lowing 3 years. Malaria incidence was approximately 15 
per 1,000 Eritreans in 2014 and 2015 but dropped to 
8.8 in 2016, although 5,178 asylum applicants regis-
tered in the same year.
The Netherlands
The Netherlands received between 1,925 and 7,455 
asylum applications from Eritreans in 2014 to 2016, in 
parallel with a marked increase in the total number of 
malaria cases represented by P. vivax, whereas for other 
malaria species, no increase was seen. The median 
age in the group of Eritreans with P. vivax malaria was 
20 years in the period 2014 to 2016 and male sex was 
more common than female. In contrary to most other 
countries, the Netherlands reported incidence rates 
similar to 2014 and 2015 also during 2016 with an inci-
dence rate of 23.9 (17.5–31.9).
Norway
Norway received approximately 3,000 Eritrean asylum 
applicants per year in the years 2013 to 2015. Despite 
similar numbers of asylum applications during these 
years, the increase in malaria cases did not occur until 
2014. Analysis of malaria incidence rates revealed 4.0 
(95% CI: 2.1–6.8), 18.4 (95% CI: 13.8–24.1) and 11.9 
(95% CI: 8.3–16.5) per 1,000 Eritreans in 2013, 2014 
and 2015, respectively. Data for 2016 as well as data 
on age and sex were not available.
Denmark
Denmark received increasing numbers of Eritrean asy-
lum applications in 2014 (n = 2,275) compared to pre-
vious years where maximum annual number was 85. 
Malaria incidence was 14.5–17.0 per 1,000 Eritreans 
in 2014 to 2015 and continuously high (43.1 per 1,000 
but with wide CI) in 2016. Out of 74 cases during 2014 
to 2016 50 were male and the median age during the 
same period was 24 years. However, only 255 Eritreans 
sought asylum in Denmark in 2016.
United Kingdom
The UK received 3,280 and 3,270 asylum applications 
from Eritrean citizens in 2014 and 2015 respectively. 
The UK was the country with the highest overall annual 
number of malaria cases, but the increase was not as 
pronounced, with 1,501 cases in 2013 and 1,586 cases 
in 2014 (p  =  0.13). This increase was not significant, 
but country of birth was missing for a large proportion 
of cases (reported in 4,010/7,537 (53.2%) of cases in 
2011–2015). When malaria incidence malaria among 
Eritreans was calculated, it was lower compared to 
the other countries studied (6.1, 5.4 and 10.0 /1,000 
in the years 2014, 2015 and 2016) with low numbers of 
registered cases among Eritreans (20 per year in 2014 
and 2016 and 13 in 2016). The majority of patients were 
male (18/20 in both 2015 and 2016),  P. vivax  was the 
dominating species among Eritreans and age median 
age in this group was 20 years in 2014 and 21 years in 
both 2015 and 2016.
Discussion
This analysis of European data on annual asylum seek-
ers and imported malaria cases revealed a sudden and 
significant rise in malaria cases in seven European 
countries during 2014 and 2015. The increase was 
mainly explained by  P. vivax  cases in Eritreans. The 
seven countries accounted for 93% of applications 
from Eritrean asylum seekers in Europe. We found 
that the increase in malaria cases was not only due to 
a higher number of asylum applications compared to 
previous years; there was also a substantial increase 
in the proportion of Eritreans affected by the disease, 
Figure 1
Incidence of malaria cases per 1,000 Eritrean asylum 












































































The black lines indicate the 95% confidence intervals.
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especially among young male adults and adolescents. 
The patients reported migrating from Eritrea through 
Ethiopia and/or Sudan and Libya before arriving in 
Europe, and many had repeated febrile episodes on 
their migration route. The review of medical records in 
Germany and Sweden found a relatively high proportion 
of severe P. vivax malaria, predominantly characterised 
by severe anaemia, and more frequently in Sweden 
compared to Germany. The difference in proportion of 
severe cases is surprising and could imply that malaria 
diagnosis was delayed in Sweden, or because the data 
was collected in two different settings. Importantly, 
low haemogloblin levels were associated with longer 
symptom duration.
Our analysis of national surveillance data and medi-
cal records is consistent with previous reports of  P. 
vivax  clusters in Eritrean migrants in Europe in 2014 
[4-6] as well as more recent national reports [7-9], and 
provides a more complete and detailed picture. The 
estimated mean incidence rate in the seven countries 
in the study increased from 2 malaria cases per 1,000 
Eritrean asylum applications in 2013 to 18 cases per 
1,000 in 2014. In 2016, although the number of Eritrean 
asylum applications remained high in some countries 
such as Germany, the number of malaria cases in this 
group dropped markedly, suggesting either changes in 
the epidemiology of malaria along the route of migra-
tion or a possible change in migration routes. We esti-
mated that there were at least 1,500 malaria cases in 
Europe during 2014 and 2015 that can be attributed 
to newly arrived Eritreans. However, the number of 
malaria cases in Eritrean migrants in Europe during 
this period is likely to be even higher, as an unknown 
number of arriving Eritreans might have sought medical 
care in countries along their migration route, as reports 
Table 2














Age in years, median (range) 21 (2–61) 19 (12–52) 0.84
Proportion males 154/210 44/52 0.11
Infection due to species of malaria
Plasmodium vivax 186 52 NA
Plasmodium falciparum 9 0  NA
Plasmodium ovale 9 0  NA
Mixed Plasmodium vivax and Plasmodium falciparum 6 0  NA
Migration route from Eritrea
Via Sudan and Libya 68 21 0.08
Via Ethiopia, Sudan and Libya 97 14  NA
Missing data 45 17  NA
Migration duration in months, median (range) 4 (1–72) 6 (1–10) 0.56
Malaria treatment during migration
Treated once 80 18 0.002
Treated 2–6 times 25 20  NA
Missing data 55 6 NA
Clinical symptoms and laboratory findings
Symptom duration at diagnosis in days, median (range) 3 (0–180) 3 (1–180) 0.829
Haemogloblin g/L, median (range) (normal values 117-170) 114 (37–171) 125 (55–161) 0.004
Platelet count number x 109/µl, median (range) ((normal values 150-400) 105 (5–289) 118 (23–380) 0.52
Severe malaria according to WHO criteria 20 1 0.07
Severe Plasmodium vivax 18 1  NA
Severe mixed infection (Plasmodium falciparum and P. vivax) 2 0  NA
Severe anaemia 11 1  NA
Other criteria for severe malaria 9 0 NA
Preventive anti-relapse treatment (primaquine) prescribed 173 51 1.000
Relapse after treatment 17 4 0.352
WHO: World Health Organization; NA: no analysis performed.
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from Italy suggest [13]. Part of the increase might be 
due to greater awareness and increased testing by 
clinicians or microbiological laboratories in parallel 
with the greater number of cases that were diagnosed 
from 2014 onwards. A limitation of this report is that 
countries were selected based on registered asylum 
applications from Eritreans and furthermore, detailed 
data was available only for Germany and Sweden. 
Nonetheless, the seven EU/EFTA countries receiving 
93% of Eritrean asylum applicants contributed data.
Patients in Hamburg (Germany) and Sweden reported 
migrating from Eritrea through Ethiopia and/or Sudan 
and Libya before arriving in Europe. According to the 
WHO World Malaria Report, P. vivax accounted for 26% 
of clinical malaria cases in Eritrea, 41% in Ethiopia and 
5% in Sudan in 2014 [14]. Clusters of  P. vivax  malaria 
cases in Eritreans have previously been reported in 
Israel and Jordan [15-17]. To our knowledge, there have 
been no reports published on epidemics or increased P. 
vivax  incidence in Eritrea, Ethiopia or Sudan during 
2014 and 2015, but rather a decline in transmission has 
been observed [14]. Libya is considered to be malaria-
free, although recent case reports raise suspicion of 
autochthonous P. falciparum and P. vivax transmission 
in the country [18]. The high incidence in Eritrean asy-
lum applicants (higher than in Eritrea) thus suggests 
some high-level local malaria transmission along 
their route of migration, possibly in eastern Ethiopia 
where P. vivax transmission is reported to be high [1].
Malaria was predominantly diagnosed in male teen-
agers with 1 case in 20 male asylum applicants. Lack 
of acquired immunity in adolescents who have grown 
up in Eritrea where malaria transmission is low [14] 
may have contributed to a particularly high level of 
vulnerability in this group to parasite exposure dur-
ing migration. Noteworthy, many patients reported 
that they were already suffering from malaria attacks 
during migration, and treatment of P. vivax,not includ-
ing radical cure of hypnozoites, may have resulted in 
relapsing infections. Indeed, analysis of weekly data in 
Sweden revealed that the P. vivax cases were predicted 
by the number of asylum applications from Eritreans 5 
weeks prior to the actual malaria notifications, which 
may reflect relapses rather than primary infections, 
in particular considering that most patients had left 
malaria-endemic areas several months earlier. Stress 
and generally impaired health status of the host dur-
ing and immediately after the migration process could 
be possible contributions to relapses of malaria [19]. 
Our findings highlight the need to focus and report on 
active malaria transmission on migration routes and 
to promote local interventions. Countries receiving 
migrants from Africa need to be aware that the epide-
miology of imported malaria may change rapidly and 
that relapses of P. vivax can occur several months after 
arrival in Europe.
The geographical patterns of imported malaria in 
Europe were recently modelled using national sta-
tistics [20]. Despite covering the same time period, 
modelling from aggregated data did not seem to cap-
ture the high number of  P. vivax  cases in a particular 
migrant group. Indeed, using only reported country of 
infection (especially only one country) has limitations 
as reflected by our comparison: clinical medical 
records and notification data showed coherence of the 
Figure 2
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country of infection in only 35% of patients (reflecting 
limitations both in medical recordings and notifica-
tion data). If this data can be collected, it could result 
in better risk assessment and more rapid detection 
of infections, in particular among vulnerable migrant 
groups.
Europe was declared malaria-free by WHO in 2016 [21]. 
Nonetheless,  Anopheles  mosquitoes with competence 
in malaria transmission are present in large parts of 
Europe [22]. A proportion of migrants in Sweden and 
Germany did not attend treatment follow-up and had 
unclear compliance regarding primaquine. As relapse 
frequency after treatment is 7–8% this might possibly 
be a public health issue. The risk of secondary cases 
in some parts of Europe thus exists but is relatively 
small; public health professionals need to be aware 
of the entomology data and which mosquito species 
are present in their area of responsibility and should 
develop strategies to successful eradication treatment 
of P. vivax [1,22].
Our review of medical records showed that severe 
malaria cases and repeated episodes were common. 
Haemogloblin levels correlated with symptom dura-
tion and a high proportion of severe anaemia requiring 
blood transfusions in Sweden is believed to be a result 
of prolonged symptoms and/or repeated episodes 
which are factors known to contribute to vivax anaemia 
[23]. Healthcare and general conditions are expected to 
be poor for refugees during migration, and displaced 
populations have been reported to be at increased 
risk of malaria [24]. Any febrile patients (including 
refugees) who have travelled through or arrived from 
Figure 3
Number of (A) malaria, (B) Plasmodium vivax and (C) Plasmodium falciparum cases diagnosed in Sweden by reported 
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malaria-endemic areas must be thoroughly investi-
gated, including a blood test for malaria. Clinicians 
and healthcare workers need to be aware of potentially 
severe symptoms. Screening refugees or asylum seek-
ers arriving from malaria endemic areas could con-
tribute to a more rapid diagnosis and treatment, and 
migrant populations from other parts of Africa or the 
Indian subcontinent could be considered. Irrespective 
of this, it is important to ensure migrants’ access to 
healthcare, especially for potentially severe diseases, 
on the basis of the international human rights law 
regarding migrants’ right to health [25].
In conclusion, we report a remarkably high incidence 
of vivax malaria among newly arrived Eritrean asylum 
seekers in Europe during 2014 and 2015. Policy mak-
ers as well as individual healthcare workers need to be 
prepared for rapid changes in the patterns of imported 
malaria, and possibly other infectious diseases, in 
migrants and particularly in refugees and asylum seek-
ers who may have undertaken long journeys through 
several countries to Europe.
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